All In Biotech

Drug Trial Radar · NCT06079476

A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.

An Open-label, Single-arm, Multicenter Phase 4 Study to Evaluate Safety and Tolerability of Romosozumab (EVENITY® ) in Postmenopausal Women in India With Osteoporosis and a High Risk of Fracture.

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

100

Actual

Start

Oct 30, 2023

Primary completion

Oct 18, 2025

Study completion Oct 18, 2025

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Oct 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to characterize safety and tolerability of romosozumab in postmenopausal women with osteoporosis and a high risk of fracture in India.

Conditions

  • Postmenopausal Osteoporosis

Interventions

  • RomosozumabDrug

    Single-use prefilled syringe for SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
  2. Number of Participants Who Experienced Treatment-emergent Serious Adverse Events (TESAEs)Time frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
  3. Number of Participants Who Experienced Clinically Significant Changes in Laboratory AssessmentsTime frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
  4. Number of Participants Who Experienced Clinically Significant Changes in Vital SignsTime frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Stavya Spine Hospital and Research Institute SSHRI

    Ahmedabad, Gujarat, India

  • MS Ramaiah Medical College and Hospitals

    Bangalore, Karnataka, India

  • King Edward Memorial Hospital And Seth Gordhandas Sunderdas Medical College

    Mumbai, Maharashtra, India

  • Sancheti Institute for Orthopedics and rehabilitation

    Pune, Maharashtra, India

  • Sir Ganga Ram Hospital

    New Delhi, National Capital Territory of Delhi, India

  • Apollo Hospital

    New Delhi, National Capital Territory of Delhi, India

  • Post Graduate Institute of Medical Education and Research

    Chandigarh, Punjab, India

  • MGM Healthcare

    Chennai, Tamil Nadu, India

  • Christain Medical College

    Vellore, Tamil Nadu, India

  • King Georges Medical University

    Lucknow, Uttar Pradesh, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.